Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Vera Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BRISBANE, CALIF., NOV. 10, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING TRANSFORMATIVE TREATMENTS FOR PATIENTS WITH SERIOUS IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT TEAM WILL PRESENT AT THE TD COWEN IMMUNOLOGY & INFLAMMATION SUMMIT, WHICH IS TAKING PLACE VIRTUALLY FROM NOVEMBER 12-13, 2025.

VERA THERAPEUTICS TO PARTICIPATE IN THE TD COWEN IMMUNOLOGY & INFLAMMATION SUMMIT

ATACICEPT RECEIVED FDA BREAKTHROUGH THERAPY DESIGNATION FOR THE TREATMENT OF IGAN ORIGIN PHASE 3 TRIAL MET ITS PRIMARY ENDPOINT AT THE PRESPECIFIED INTERIM ANALYSIS OF PROTEINURIA REDUCTION WITH 46% REDUCTION FROM BASELINE AND 42% REDUCTION VS PLACEBO AT WEEK 36 (P

VERA THERAPEUTICS SUBMITS BIOLOGICS LICENSE APPLICATION TO U.S. FDA THROUGH ACCELERATED APPROVAL PROGRAM FOR ATACICEPT FOR THE TREATMENT OF ADULTS WITH IGA NEPHROPATHY

BRISBANE, CALIF., NOV. 07, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT, ON NOVEMBER 4, 2025, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF VERA THERAPEUTICS GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 79,050 SHARES OF CLASS A COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) UNDERLYING 39,915 SHARES OF CLASS A COMMON STOCK TO SIX (6) NEW EMPLOYEES UNDER THE VERA THERAPEUTICS, INC. 2024 INDUCEMENT PLAN (INDUCEMENT PLAN). THE COMPENSATION COMMITTEE APPROVED THE AWARDS AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES' EMPLOYMENT IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

VERA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

BRISBANE, CALIF., NOV. 06, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED DATA FROM THE ORIGIN PHASE 3 TRIAL OF ATACICEPT IN IGA NEPHROPATHY (IGAN) WERE PRESENTED AS A FEATURED LATE-BREAKING ORAL PRESENTATION DURING THE OPENING PLENARY SESSION OF THE AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK 2025 AND SIMULTANEOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE (NEJM).

VERA THERAPEUTICS ANNOUNCES POSITIVE ORIGIN PHASE 3 DATA FOR ATACICEPT IN IGA NEPHROPATHY PRESENTED AT ASN KIDNEY WEEK 2025 AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

ORIGIN 3 TRIAL PRIMARY ENDPOINT RESULTS FOR ATACICEPT IN IGA NEPHROPATHY (IGAN) SELECTED AS A FEATURED LATE-BREAKING ORAL PRESENTATION DURING OPENING PLENARY SESSION OF AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK 2025 BIOLOGICS LICENSE APPLICATION (BLA) SUBMISSION THROUGH THE ACCELERATED APPROVAL PROGRAM FOR ATACICEPT FOR THE TREATMENT OF IGAN TO U.S. FDA EXPECTED IN Q4; POTENTIAL U.S. COMMERCIAL LAUNCH OF ATACICEPT IN 2026 ACTIVELY ENROLLING PATIENTS IN THE PIONEER, ATACICEPT MONTHLY DOSE RANGE FINDING, AND ORIGIN EXTEND STUDIES BRISBANE, CALIF., NOV. 05, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING TRANSFORMATIVE TREATMENTS FOR PATIENTS WITH SERIOUS IMMUNOLOGICAL DISEASES, TODAY REPORTED ITS BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025.

VERA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

BRISBANE, CALIF., OCT. 22, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING TRANSFORMATIVE TREATMENTS FOR PATIENTS WITH SERIOUS IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT IT WILL HOST AN INVESTOR CALL AND WEBCAST AT 4:30 PM ET ON THURSDAY, NOVEMBER 6, 2025 TO REVIEW THE DATA FROM THE ORIGIN PHASE 3 CLINICAL TRIAL OF ATACICEPT FOR THE TREATMENT OF IGA NEPHROPATHY (IGAN) PRESENTED AT THE MORNING PLENARY SESSION AT THE AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK 2025.

VERA THERAPEUTICS TO HOST AN INVESTOR CALL AND WEBCAST TO PROVIDE AN ORIGIN 3 UPDATE ON NOVEMBER 6, 2025 AT 4:30 PM ET

BRISBANE, CALIF., OCT. 17, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING TRANSFORMATIVE TREATMENTS FOR PATIENTS WITH SERIOUS IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT DATA FROM THE ORIGIN PHASE 3 CLINICAL TRIAL OF ATACICEPT FOR THE TREATMENT OF IGA NEPHROPATHY (IGAN) WILL BE DELIVERED AS A FEATURED LATE-BREAKING ORAL PRESENTATION DURING THE OPENING PLENARY SESSION OF THE AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK 2025 IN HOUSTON, TEXAS, BEING HELD NOVEMBER 6 TO 9.

VERA THERAPEUTICS ANNOUNCES ORIGIN 3 LATE-BREAKING ABSTRACT SELECTED AS FEATURED ORAL PRESENTATION AT OPENING PLENARY SESSION OF ASN KIDNEY WEEK 2025

BRISBANE, CALIF., OCT. 10, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT, ON OCTOBER 6, 2025, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF VERA THERAPEUTICS GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 135,100 SHARES OF CLASS A COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) UNDERLYING 70,775 SHARES OF CLASS A COMMON STOCK TO TWENTY-ONE (21) NEW EMPLOYEES UNDER THE VERA THERAPEUTICS, INC. 2024 INDUCEMENT PLAN (INDUCEMENT PLAN). THE COMPENSATION COMMITTEE APPROVED THE AWARDS AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES' EMPLOYMENT IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

Vera Therapeutics, Inc.

VERA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Vera Therapeutics, Inc.

VERA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

VERA